JP2023552554A - フィツシランを用いた血友病の処置 - Google Patents

フィツシランを用いた血友病の処置 Download PDF

Info

Publication number
JP2023552554A
JP2023552554A JP2023534111A JP2023534111A JP2023552554A JP 2023552554 A JP2023552554 A JP 2023552554A JP 2023534111 A JP2023534111 A JP 2023534111A JP 2023534111 A JP2023534111 A JP 2023534111A JP 2023552554 A JP2023552554 A JP 2023552554A
Authority
JP
Japan
Prior art keywords
fitusiran
patient
patients
subcutaneously
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552554A5 (cg-RX-API-DMAC7.html
Inventor
ステイシー・ポロスキー
ショーナ・アンデション
プラティック・アール・ベガンド
ユエ・ツイ
サジダ・イクバール
バイソン・メイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2023552554A publication Critical patent/JP2023552554A/ja
Publication of JP2023552554A5 publication Critical patent/JP2023552554A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8128—Antithrombin III
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023534111A 2020-12-06 2021-12-06 フィツシランを用いた血友病の処置 Pending JP2023552554A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063121973P 2020-12-06 2020-12-06
US63/121,973 2020-12-06
US202163272629P 2021-10-27 2021-10-27
US63/272,629 2021-10-27
US202163275344P 2021-11-03 2021-11-03
US63/275,344 2021-11-03
PCT/US2021/062078 WO2022120292A1 (en) 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran

Publications (2)

Publication Number Publication Date
JP2023552554A true JP2023552554A (ja) 2023-12-18
JP2023552554A5 JP2023552554A5 (cg-RX-API-DMAC7.html) 2024-12-13

Family

ID=80112089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534111A Pending JP2023552554A (ja) 2020-12-06 2021-12-06 フィツシランを用いた血友病の処置

Country Status (10)

Country Link
US (1) US20240027478A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552554A (cg-RX-API-DMAC7.html)
KR (1) KR20230117403A (cg-RX-API-DMAC7.html)
AU (1) AU2021391951A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204344A1 (cg-RX-API-DMAC7.html)
IL (1) IL303452A (cg-RX-API-DMAC7.html)
MX (1) MX2023006651A (cg-RX-API-DMAC7.html)
TW (1) TW202237151A (cg-RX-API-DMAC7.html)
WO (1) WO2022120292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3258425A1 (en) * 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran in pediatric patients
EP4612687A1 (en) 2022-11-02 2025-09-10 Genzyme Corporation Systems and methods for modeling thrombin-antithrombin
TW202525306A (zh) * 2023-09-15 2025-07-01 美商健臻公司 用非妥西蘭(fitusiran)治療a型血友病
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200163987A1 (en) * 2017-07-10 2020-05-28 Genzyme Corporation Methods and compositions for treating a bleeding event in a subject having hemophilia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200163987A1 (en) * 2017-07-10 2020-05-28 Genzyme Corporation Methods and compositions for treating a bleeding event in a subject having hemophilia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Alnylam Initiates Fitusiran (ALN-AT3) Dosing on Hemophilia A and B Patients with Inhibitors in Ongoi", ALNYLAM PHARMACEUTICAL PRESS RELEASE, [ONLINE], JPN6026004829, 14 May 2016 (2016-05-14), ISSN: 0005793283 *
BHAGUNDE P; ET AL: "PB0526 / FITUSIRAN POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC (POPPK/PD) MODELING 以下備考", RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS - ABSTRACTS OF THE 64TH ANNUAL MEETING 以下省略, vol. VOL.5, NR.S2, JPN5024006870, October 2021 (2021-10-01), GB, pages 399 - 400, ISSN: 0005793285 *
NATURE MEDICINE, vol. 21, no. 5, JPN6026004828, 2015, pages 492 - 497, ISSN: 0005793282 *
PASI K J; ET AL: "TARGETING OF ANTITHROMBIN IN HEMOPHILIA A OR B WITH RNAI THERAPY", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL.377, NR.9, JPN5024006869, 10 July 2017 (2017-07-10), pages 819 - 828, ISSN: 0005793281 *
SRIDHARAN G; ET AL: "P093 / MODELING THE IMPACT OF FACTOR ADMINISTRATION AND ANTITHROMBIN LEVEL ON THROMBIN GENERATION", HAEMOPHILIA, vol. 24, JPN5024006868, February 2018 (2018-02-01), GB, pages 75 - 76, ISSN: 0005793284 *

Also Published As

Publication number Publication date
TW202237151A (zh) 2022-10-01
EP4255566A1 (en) 2023-10-11
US20240027478A1 (en) 2024-01-25
AU2021391951A1 (en) 2023-07-20
IL303452A (en) 2023-08-01
KR20230117403A (ko) 2023-08-08
AU2021391951A9 (en) 2024-05-02
MX2023006651A (es) 2023-08-02
WO2022120292A1 (en) 2022-06-09
CA3204344A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
KR20230117403A (ko) 피투시란을 이용한 혈우병의 치료
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
JP2023531679A (ja) 血友病を処置するための方法および組成物
JP2025519491A (ja) 小児患者における血友病a及びbの処置のためのフィツシラン
US20240000744A1 (en) Treatment of Hemophilia with Fitusiran
US20210187083A1 (en) Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
TW202525306A (zh) 用非妥西蘭(fitusiran)治療a型血友病
JP2025500412A (ja) 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン
CN116635040A (zh) 用非妥西兰治疗血友病
TW202237149A (zh) 用於治療出血性障礙之組成物及方法
EP3581196A1 (de) Inhibitoren des transferrinrezeptor-2 zur verwendung bei der behandlung von erkrankungen des knochens, des eisenstoffswechsels und der blutbildung
HK40056298A (en) Modified factor vii polypeptides for subcutaneous administration
HK40056298B (en) Modified factor vii polypeptides for subcutaneous administration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260810